New perspective of GABA as an inhibitor of formation of advanced lipoxidation end-products: It's interaction with malondiadehyde

Journal of Biomedical Nanotechnology

Volumn 6, Issue 4, 2010, Pages 318-324

  Deng, Yan ^a,b   Xu, Lijian ^b   Zeng, Xin ^a   Li, Zhiyang ^a   Qin, Binbing ^a   He, Nongyue ^a,b  

^a SOUTHEAST UNIVERSITY   (China)

^b HUNAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Gamma Aminobutyric Acid (GABA); Lipid peroxidation; Malondialdehyde (MDA); Reactive carbonyl compounds; Scavenging

Indexed keywords

AMINOBUTYRIC ACIDS; DIHYDROPYRIDINES; DIRECT REACTIONS; ENAMINES; END-PRODUCTS; GAMMA-AMINOBUTYRIC ACIDS; IN-VITRO; LIPID PEROXIDATION; MALONDIALDEHYDE; MALONDIALDEHYDE (MDA); NUTRACEUTICALS; POTENT ANTIOXIDANTS; REACTION MIXTURE; REACTIVE CARBONYL COMPOUNDS; REACTIVE INTERMEDIATE; SCAVENGING EFFECT;

ALDEHYDES; AMINO ACIDS; CARBONYLATION; CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OXIDATION; OXIDATIVE STRESS; POLYUNSATURATED FATTY ACIDS; REACTION INTERMEDIATES;

FATTY ACIDS;

1,4 DIHYDROPYRIDINE; 4 AMINOBUTYRIC ACID; ADVANCED LIPOXIDATION END PRODUCT; ENAMINE; FATTY ACID; MALONALDEHYDE; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG; GABAERGIC RECEPTOR AFFECTING AGENT;

ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIPID OXIDATION; LIPID PEROXIDATION; MOLECULAR INTERACTION; PHASE SEPARATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; LIPID PEROXIDATION; MALONDIALDEHYDE; MOLECULAR STRUCTURE;

EID: 79953019755     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1130     Document Type: Article

References (56)

1. B. Halliwell and J. Gutteridge, Free Radicals in Biology and Medicine, Clarendon Press, Oxford (1989).
2. B. S. Berlett and E. R. Stadtman, Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272, 20313 (1997).
3. M. M. Anderson, J. R. Requena, J. R. Crowley, S. R. Thorpe, and J. W. Heinecke, The myeloperoxidase system of human phagocytes generates iV-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J. Clin. Invest. 104, 103 (1999).
4. M. L. Tiku, R. Shah, and G. T. Allison, Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation. Possible role in cartilage aging and the pathogenesis of osteoarthritis. J. Biol. Chem. 275, 20069 (2000).
5. H. Esterbauer, R. J. Schaur, and H. Zollner, Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biol. Med. 11, 81 (1991).
6. I. Dalle-Donne, D. Giustarini, R. Colombo, R. Rossi, and A. Milzani, Protein carbonylation in human diseases. Trends Mol. Med. 9, 169 (2003).
7. M. L. Urso and P. M. Clarkson, Oxidative stress, exercise and antioxidant supplementation. Toxicology 189, 41 (2003).
8. T. Miyata, K. Kurokawa, Y. D. Van, and C. Strihou, Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int. 58, 120 (2000).
9. D. Z. Yin, Biochemical basis of lipofuscin, ceroid, and age pigment-like fluorophores. Free Radical Biol. Med. 21, 871 (1996).
10. J. R. Requena, M. X. Fu, M. U. Ahmed, A. J. Jenkins, T. J. Lyons, and J. W. Baynes, Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem. J. 322, 317 (1997).
11. J. W. Baynes and S. R. Thorpe, Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 48, 1 (1999).
12. H. Wang, L. J. Marmett, T. M. Harris, and C. J. Rizzo, A novel synthesis of malondialdehyde adducts of deoxyguanosine, deoxyadenosine, and deoxycytidine. Chem. Res. Toxicol. 17, 144 (2004).
13. R. Ahmad, A. K. Tripathi, P. Tripathi, S. Singh, R. Singh, and R. K. Singh, Malondialdehyde and protein carbonyl as biomarkers for oxidative stress and disease progression in patients with chronic myeloid leukemia. In Vivo 22, 525 (2008).
14. S. E. Browne, R. J. Ferrante, and M. F. Beal, Oxidative stress in Huntington's disease. Brain Pathol. 9, 147 (1999).
15. V. Medina-Hernández, J. Ramos-Loyo, S. Luquin, L. F. Sánchez, J. García-Estrada, and A. Navarro-Ruiz, Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics. J. Psychiatr. Res. 41, 652 (2007).
16. K. Hayakawa, M. Kimura, K. Kasaha, K. Matsumoto, H. Sansawa, and Y Yamori, Effect of a γ-aminobutyric acid-enriched dairy product on the blood pressure of apontaneously hypertensive and normotensive istar-Kyoto rats. British J. Nutrition 92, 411 (2004).
17. T. Tojiro, M. Toshinobu, and H. Mitsuru, Effect of anaerobically treated tes (Gabaron Tea) on blood pressure of spontaneously hypertensive rats. Nippon Nogeikagaku Kaishi 61, 1149 (1987).
18. A. G. Leventhal, Y. Wang, M. Pu, Y. Zhou, and Y. Ma, GABA and its agonists improved visual cortical function in senescent monkeys. Science 300, 812 (2003).
19. O. Tadashi and S. Tomoda, Effect of defatted rice germ enriched with GABA for aleeplessness, depression, autonomic disorder by oral administration. Nippon Shokuhin Kagaku Kogaku Kaishi 47, 596 (2000).
20. F. V. DeFeudis, gamma-Aminobutyric acid and cardiovascular function. Experientia 39, 845 (1983).
21. T. Hua, C. Kao, Q. Sun, X. Li, and Y. Zhou, Decreased proportion of GABA neurons accompanies age-related degradation of neuronal function in cat striate cortex. Brain Res. Bull. 75, 119 (2008).
22. K. Kikugawa and M. Beppu, Involvment of lipid oxidative products in the formation of fluorescent and cross-linked proteins. Chem. Phys. Lipids 44, 277 (1987).
23. J. M. Onorato, A. J. Jenkins, S. R. Thorpe, and J. W. Baynes, Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J. Biol. Chem. 275, 21177 (2000).
24. R. M. LoPachin, D. S. Barber, and T. Gavin, Molecular mechanisms of the conjugated a,b-unsaturated carbonyl derivatives: Relevance to neurotoxicity and neurodegenerative diseases. Toxicol. Sci. 104, 235 (2008).
25. G. Poli and M. Parola, Oxidative damage and fibrogenesis. Free Radical Biol. Med. 22, 287 (1997).
26. Q. Zhu, C. P. Liang, K. W. Cheng, X. F. Peng, C. Y. Lo, F. Shahidi, F. Chen, C. T. Ho, and M. F. Wang, Trapping effects of green and black tea extracts on peroxidation-derived Carbonyl substances of seal blubber oil. J. Agric. Food chem. 57, 1065 (2009).
27. K. Kikugawa,. K. Tsukuda, and T. Kurechi, Studies on peroxidized lipids. 1. Interaction of malondialdehyde with secondary amine and its relevance to nirtosamine formation. Chem. Pharm. Bull. 28, 3323 (1980).
28. K. Kikugawa, T. Maruyama, Y. Machida, and T. Kurechi, Studies on peroxidized lipids. 2. Fluorescent pigments relevant to aging pigments derived from the reaction of malondialdehyde and methylamine. Chem. Pharm. Bull. 29, 1423 (1981).
29. C. Fang, M. J. Peng, G. L. Li, J. Z. Tian, and D. Z. Yin, New functions of glucosamine as a scavenger of the lipid peroxidation product malondialdehyde. Chem. Res. Toxicol. 20, 947 (2007).
30. K. Itakura, K. Uchida, and T. Osawa, A novel fluorescent malondialdehyde-lysine adduct. Chem. Phys. Lipids 84, 75 (1996).
31. D. Xu, G. M. Thiele, M. L. Kearly, M. D. Haugen, L. W. Klassen, and M. F. Sorrell, Epitope characterization of malondialdehydeacetaldehyde adducts using an enzyme linked immunosorbent assay. Chem. Res. Toxicol. 10, 978 (1997).
32. D. Tuma, G. Thiele, D. Xu, L. Klassen, and M. Sorrell, Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long-term ethanol administration. Hepatology 23, 872 (1996).
33. D. A. Slatter, M. Murray, and A. J. Bailey, Formation of a dihydropyridine derivative as a potential cross-link derived from malondialdehyde in physiological systems. FEBS Lett. 421, 180 (1998).
34. M. Ischia, A. Napolitano, and C. Costantini, Reactions of malondialdehyde with amine neurontransmitters. Formation and oxidation chemistry of fluorescent 1,4-dihydropyridine adducts. Tetrahedron 51, 9501 (1995).
35. N. Kalaji, A. Deloge, N. Sheibat-Othman, O. Boyron, I. About, and H. Fessi, Controlled release carriers of growth factors FGF-2 and TGF 1: Synthesis, characterization and kinetic modelling. J. Biomed. Nanotechnol. 6, 106 (2010).
36. X. Liu, K. Nakamura, Y. Wang, D. Cheng, M. Liang, N. Xiao, L. Chen, M. Rusckowski, and D. J. Hnatowich, Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle. J. Biomed. Nanotechnol. 6, 153 (2010).
37. S. Ilbasmis-Tamer, S. Yilmaz, E. Banoglu, and I. T. Degim, Carbon nanotubes to deliver drug molecules. J. Biomed. Nanotechnol. 6, 20 (2010).
38. K. Ruckmani, V. Sankar, and M. Sivakumar, Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes. J. Biomed. Nanotechnol. 6, 43 (2010).
39. O. Mykhaylyk, A. Steingötter, H. Perea, J. Aigner, R. Botnar, and C. Plank, Nucleic acid delivery to magnetically-labeled cells in a 2D array and at the luminal surface of cell culture tube and their detection by MRI. J. Biomed. Nanotechnol. 5, 692 (2009).
40. P. Wu, X. He, K. Wang, W. Tan, C. He, and M. Zheng, A novel methotrexate delivery ystem based on chitosan-methotrexate covalently conjugated nanoparticles. J. Biomed. Nanotechnol. 5, 557 (2009).
41. W. Yang, T. Wang, J. Fu, and N. He, Chitosan/sodium tripolyphosphate nanoparticles: Preparation, characterization and application as drug carrier, J. Biomed. Nanotechnol. 5, 591 (2009).
42. E. B. Souto, P. Martins-Lopes, C. M. Lopes, I. Gaivão, A. M. Silva, and H. Guedes-Pinto, A note on regulatory concerns and toxicity assessment in lipid-based delivery systems (LDS). J. Biomed. Nanotechnol. 5, 317 (2009).
43. P. Blasi, A. Schoubben, S. Giovagnoli, C. Rossi, and M. Ricci, Lipid nanoparticles for drug delivery to the brain: In vivo Veritas. J. Biomed. Nanotechnol. 5, 344 (2009).
44. L. Jorgensen, S. Martins, and M. van de Weert, Analysis of protein physical stability in lipid based delivery systems - the challenges of lipid drug delivery systems. J. Biomed. Nanotechnol. 5, 401 (2009).
45. N. Csaba, M. Köping-Höggård, E. Fernandez-Megia, R. Novoa-Carballal, R. Riguera, and M. J. Alonso, Ionically crosslinked chitosan nanoparticles as gene delivery systems: Effect of PEGylation degree on in vitro and in vivo gene transfer. J. Biomed. Nanotechnol. 5, 162 (2009).
46. B. Wang, M. Gou, X. Zheng, X. Wei, C. Gong, X. Wang, Y. Zhao, F. Luo, L. Chen, Z. Qian, and L. Yang, Co-delivery honokiol and doxorubicin in MPEG-PLA nanoparticles. J. Nanosci. Nanotechnol. 10, 4166 (2010).
47. S. Fu, G. Guo, X. Wang, L. Zhou, T. Liu, P. Dong, F. Luo, Y. Gu, X. Shi, X. Zhao, Y. Wei, and Z. Qian, Preparation and characterization of n-hydroxyapatite/PCL-pluronic-PCL nanocomposites for tissue engineering. J. Nanosci. Nanotechnol. 10, 711 (2010).
48. M. Gou, L. Wu, Q. Yin, Q. Guo, G. Guo, J. Liu, X. Zhao, Y. Wei, and Z. Qian, Transdermal anaesthesia with lidocaine nano-formulation pretreated with low-frequency ultrasound in rats model. J. Nanosci. Nanotechnol. 9, 6360 (2009).
49. X. Li, X. Zheng, X. Wei, G. Guo, M. Gou, C. Gong, X. Wang, M. Dai, L. Chen, Y. Wei, and Z. Qian, A novel composite drug delivery system: Honokiol nanoparticles in thermosensitive hydrogel based on chitosan. J. Nanosci. Nanotechnol. 9, 4586 (2009).
50. N. He, T. Wang, L. Jiang, D. Wang, Y. Hu, and L. Zhang, Therapy for cerebral ischemic injury with erythropoietin-containing nanopariticles, J. Nanosci. Nanotechnol. 10, 5320 (2010).
51. T. Wang, Z. Feng, N. He, Z. Wang, S. Li, Y. Guo, and L. Xu, A novel preparation of nanocapsules from alginate-oligochitosan, J. Nanosci. Nanotechnol. 1, 4571 (2007).
52. T. Wang and N. He, Low molecular weight alginate-oligochitosan nanocapsules: Preparation, characterization and applications, Nanoscale 2010, 230 (2010).
53. T. Wang, Y. Hu, L. Zhang, L. Jiang, Z. Chen, and N. He, Erythropoietin nanopariticles: Therapy for cerebral ischemic injury and metabolism in kidney and liver, Nano Biomed. Eng. 2, 31 (2010).
54. R. Jain and V. B. Patravale, Development and evaluation of nitrendipine nanoemulsion for intranasal delivery. J. Biomed. Nanotechnol. 5, 62 (2009).
55. U. Mukesh, V. Kulkarni, R. Tushar, and R. S. R. Murthy, Methotrexate loaded self stabilized calcium phosphate nanoparticles: A novel inorganic carrier for intracellular drug delivery. J. Biomed. Nanotechnol. 5, 99 (2009).
56. G. Bhakta. A. Shrivastava, and A. Maitra, Magnesium phosphate nanoparticles can be efficiently used in vitro and in vivo as non-viral vectors for targeted gene delivery. J. Biomed. Nanotechnol. 5, 106 (2009).